Published On: 6/11/2024
EASL 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR
Lead author and member of the TARGET-NASH steering committee, A. Sidney Barritt IV, MD, MSCR, presented a new Target RWE study analysis at EASL 2024 titled “Real-World Use of Glucagon Like Peptide 1 Receptor Agonist in Patients with MASLD: A Cross-Sectional Analysis from Target NASH.”
The study analyzed the use of GLP-1 receptor agonists in real world patients diagnosed with MASL, metabolic dysfunction-associated steatohepatitis (MASH), and MASLD with cirrhosis – finding that 11% of the adult cohort were prescribe GLP-1 therapy. Watch this video presentation by Dr. Barritt highlighting the important study:
About Target RWE
Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy.
Visit our website to learn more: https://targetrwe.com/
Contact:
Kayla Slake
Senior Manager, Marketing
984.234.0268 ext 205
More News
-
12/11/2024
New Patient-Reported Outcome Insights from Target RWE: NASH-CHECK Reveals Stability Over Time and Worse Scores Among Those with Decompensated Cirrhosis of Patients with MASLD -
12/04/2024
The Liver Meeting 2024 Research: Cirrhosis Presentation by Arun J. Sanyal, MBBS, MD -
12/04/2024
The Liver Meeting 2024 Research: NASH-CHECK Presentation by Arun J. Sanyal, MBBS, MD -
12/04/2024
The Liver Meeting 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR -
12/04/2024
ACG 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR